Avacta shares fly on success for rapid Covid-19 antigen test
Shares in biotherapeutics and reagents company Avacta (AVCT:AIM) surged 22% to 189p on Tuesday after clinical trials for its rapid Covid-19 antigen test showed excellent progress.The UK and EU studies used patient samples with...
16 February 2021